Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-Related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy.

Trial Profile

Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-Related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 28 Nov 2011 Location (Venezuela) and actual patient number 38 added as reported by ClinicalTrials.gov.
    • 20 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top